Finerenone
- Generic Name
- Finerenone
- Brand Names
- Kerendia
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22N4O3
- CAS Number
- 1050477-31-0
- Unique Ingredient Identifier
- DE2O63YV8R
- Background
Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization due to heart failure in adults with chronic kidney disease associated with type II diabetes mellitus. Patients with kidney di...
- Indication
In the US, finerenone is indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization due to heart failure in adults with chronic kidney disease associated with type II diabetes mellitus.
...
- Associated Conditions
- Cardiovascular Mortality, Chronic Kidney Disease, Stage 3 (Moderate), End Stage Renal Disease (ESRD), Hospitalizations, Nonfatal Myocardial Infarction, Stage 4 Chronic Kidney Disease, Sustained creatinine renal clearance decreased
- Associated Therapies
- -
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Colorado Prevention Center
- Target Recruit Count
- 5200
- Registration Number
- NCT06008197
- Locations
- 🇺🇸
Aurora, CO Investigative Site, Aurora, Colorado, United States
🇺🇸Denver, CO Investigative Site, Denver, Colorado, United States
🇺🇸Boca Raton, FL Investigative Site, Boca Raton, Florida, United States
Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Chongqing Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT05924620
- Locations
- 🇨🇳
The First Affilated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 220
- Registration Number
- NCT05901831
- Locations
- 🇬🇧
Cardiff and Vale University Health Board - University Hospital of Wales (UHW), Cardiff, United Kingdom
🇺🇸Stanford University | Endocrinology Department - Diabetes Research, Stanford, California, United States
🇺🇸Touro University (TU) - College of Osteopathic Medicine (TUCOM) - California, Vallejo, California, United States
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
- Conditions
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Saga University
- Target Recruit Count
- 100
- Registration Number
- NCT05887817
- Locations
- 🇯🇵
Saga University Hospital, Saga, Japan
Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-18
- Target Recruit Count
- 96
- Registration Number
- NCT05814770
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.